Pharmaceutical Manufacturing Market Size is Anticipated to Hit US$ 1,190.16 Billion by 2030

The pharmaceutical manufacturing market size was USD 401.67 billion in 2021 and is expected to reach USD 1,190.16 billion by 2030. It is anticipated to grow with a healthy CAGR of 12.8% from 2021 to 2030.

In 2022, the pharmaceutical manufacturing market study provides crucial information on market share, market size, growth rate analysis Y-O-Y, production, consumption, and sales analysis for the forecast period 2021 to 2030. The report contains 150+ pages with detailed analysis.

The pharmaceutical business is a vital segment of the larger healthcare ecosystem. The pharmaceutical industry primarily deals with scientific research activities and the development of medications that avert or treat ailments and disorders. The pharmaceutical industry comprises of both private as well as public establishments that conceive, promote, produce, and retail medicines. Modern technological and scientific breakthroughs are speeding up the detection and development of innovative medications or treatments with improved healing activity and less side effects. Medicinal chemists, molecular biologists, and pharmacists work collectively for enhancing the quality and efficiency of the drugs. Pharmaceutical manufacturing is the procedure of commercial-scale creation of medicines by pharmaceutical establishments.

The growing demand for modernization of pharmaceutical manufacturing process has prompted leading companies to employ new technologies such as continuous pharmaceutical manufacturing. This technology offers probable flexibility, superiority, and economic rewards over batch processing, together in process manufacturing and expansion for the pharmaceutical sector. Since the past few years, there have been significant advancements in science and engineering to support the implementation of continuous pharmaceutical manufacturing. These advancements, together with the acceptance of the QbD paradigm for pharmaceutical progress and the development of PAT for designing, examining, and controlling production, have advanced the scientific and monitoring eagerness for continuous manufacturing.

Growth Factors:

Factors such as increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, increasing focus on outsourcing manufacturing activities, increasing per capita healthcare expenditure, growing incidence of novel viral diseases, technological advancements in manufacturing processes, and improving reimbursement scenario in developing regions are driving the growth of pharmaceutical manufacturing market. Amplified focus on elderly and pediatric patients, high incidence of cardiovascular disorders, growing demand for home-based healthcare, and increased cancer and diabetes cases are further propelling the pharmaceutical manufacturing market expansion across the globe. Additional aspects that are anticipated to fuel this industry are increasing demand for new drug delivery approaches and reformulation of injections and oral medications.

The pharmaceutical industry is predominantly motivated by scientific advancements, in combination with clinical and toxicological experience. Major variances exist between large establishments and smaller organizations. Large pharmaceutical companies participate in an extensive range of medicine discovery and development, production and quality control, promotion and sales, whereas small pharmaceutical companies focus on a precise aspect.

Future of Pharmaceutical Manufacturing

In order to deal with the challenges that advanced therapeutics, pricing burdens, and worldwide supply chains exhibit, the implementation of latest digital solutions has become vital for pharmaceutical manufacturers. It includes leveraging artificial intelligence, Big Data, machine-learning, and industrial internet of things (IIoT)for a consequential impact on pharmaceutical manufacturing process to improve quality. Contract manufacturing is expected to bring about the much-required transformation in the pharmaceutical manufacturing business.

Report Highlights Details
Market Size US$ 1,190.16 Billion by 2030
Growth Rate CAGR of 12.8% From 2021 to 2030
Base Year 2021
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Drug Development, Route of Administration, Formulation, Therapy
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)

COVID-19 Impact:

The industrial report mentions the influence of the ongoing COVID-19 pandemic. The outbreak has caused disturbances in several industries and has hammered the logistics, resulting in delayed deliveries and cancellation of product demand. The pharmaceutical manufacturing report proficiently explains the resulting factors and concerns of manufacturers. Researchers have also well-explained how the producers and providers will tackle the ongoing epidemic and the key strategies to be adopted post-pandemic for turning their businesses back to normal.

Key Players:

The pharmaceutical manufacturing market is consolidated with a major number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research.

Some of the prominent players in the pharmaceutical manufacturing market include:

  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Hoffmann-La Roche Ltd.
  • Lonza
  • Pfizer, Inc.
  • Sanofi SA
  • Novartis AG
  • AstraZeneca

Market Segmentation

By Drug Development Type

  • In-house
  • Outsource

By Route of Administration

  • Topical
  • Oral
  • Inhalations
  • Parenteral
  • Others

By Formulation

  • Injectable
  • Tablets
  • Suspensions
  • Capsules
  • Sprays
  • Others

By Therapy

  • Diabetes
  • Cardiovascular Diseases
  • Respiratory Diseases
  • Cancer
  • Pain
  • Others

Regional Segmentation

  • North America (U.S. and Canada)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Find More Press Releases at https://www.globenewswire.com/en/search/organization/Precedence%2520Research

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Pharmaceutical Manufacturing Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Pharmaceutical Manufacturing Market

5.1. Covid-19: Pharmaceutical Manufacturing Industry Impact
5.2. Pharmaceutical Manufacturing Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Pharmaceutical Manufacturing Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Pharmaceutical Manufacturing Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Pharmaceutical Manufacturing Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increasing prevalence of chronic ailments
6.1.1.2. Growing geriatric population
6.1.2. Market Restraints
6.1.2.1. Stringent Regulations
6.1.3. Market Opportunities
6.1.3.1. Increasing prevalence of chronic ailments
6.1.3.2. Growing geriatric population

Chapter 7. Global Pharmaceutical Manufacturing Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Pharmaceutical Manufacturing Market Revenue by Market Players (2016 -2019)
7.1.1.2. Pharmaceutical Manufacturing Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Drug Development Type Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Pharmaceutical Manufacturing Market, By Drug Development Type

8.1. Pharmaceutical Manufacturing Market, by Drug Development Type, 2017-2030
8.1.1. In-house
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Outsource
8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Pharmaceutical Manufacturing Market, By Route of Administration

9.1. Pharmaceutical Manufacturing Market, by Route of Administration, 2017-2030
9.1.1. Topical
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Oral
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Inhalations
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Parenteral
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Pharmaceutical Manufacturing Market, By Formulation

10.1. Pharmaceutical Manufacturing Market, by Formulation, 2017-2030
10.1.1. Injectable
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Tablets
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Suspensions
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Capsules
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Sprays
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Pharmaceutical Manufacturing Market, By Therapy

11.1. Pharmaceutical Manufacturing Market, by Therapy, 2017-2030
11.1.1. Diabetes
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Cardiovascular Diseases
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Respiratory Diseases
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Cancer
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. Pain
11.1.5.1. Market Revenue and Forecast (2017-2030)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Pharmaceutical Manufacturing Market, Regional Estimates and Trend Forecast

12.1. North America
12.1.1. Market Revenue Forecast by Drug Development Type(2017-2030)
12.1.2. Market Revenue Forecast by Route of Administration(2017-2030)
12.1.3. Market Revenue Forecast by Formulation (2017-2030)
12.1.4. Market Revenue Forecast by Therapy (2017-2030)
12.1.5. U.S
12.1.5.1. Market Revenue Forecast (2017-2030)
12.1.6. Canada
12.1.6.1. Market Revenue Forecast (2017-2030)
12.2. Europe
12.2.1. Market Revenue Forecast by Drug Development Type (2017-2030)
12.2.2. Market Revenue Forecast by Route of Administration (2017-2030)
12.2.3. Market Revenue Forecast by Formulation (2017-2030)
12.2.4. Market Revenue Forecast by Therapy (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue Forecast (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue Forecast (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue Forecast (2017-2030)
12.2.8. Rest of EU
12.2.8.1. Market Revenue Forecast (2017-2030)
12.3. Asia Pacific (APAC)
12.3.1. Market Revenue Forecast by Drug Development Type (2017-2030)
12.3.2. Market Revenue Forecast by Route of Administration (2017-2030)
12.3.3. Market Revenue Forecast by Formulation (2017-2030)
12.3.4. Market Revenue Forecast by Therapy (2017-2030)
12.3.5. China
12.3.5.1. Market Revenue Forecast (2017-2030)
12.3.6. India
12.3.6.1. Market Revenue Forecast (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue Forecast (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue Forecast (2017-2030)
12.4. LATAM
12.4.1. Market Revenue Forecast by Drug Development Type (2017-2030)
12.4.2. Market Revenue Forecast by Route of Administration (2017-2030)
12.4.3. Market Revenue Forecast by Formulation (2017-2030)
12.4.4. Market Revenue Forecast by Therapy (2017-2030)
12.4.5. Brazil
12.4.5.1. Market Revenue Forecast (2017-2030)
12.4.6. Rest of LATAM
12.4.6.1. Market Revenue Forecast (2017-2030)
12.5. Middle East and Africa (MEA)
12.5.1. Market Revenue Forecast by Drug Development Type (2017-2030)
12.5.2. Market Revenue Forecast by Route of Administration (2017-2030)
12.5.3. Market Revenue Forecast by Formulation (2017-2030)
12.5.4. Market Revenue Forecast by Therapy (2017-2030)
12.5.5. GCC
12.5.5.1. Market Revenue Forecast (2017-2030)
12.5.6. North Africa
12.5.6.1. Market Revenue Forecast (2017-2030)
12.5.7. South Africa
12.5.7.1. Market Revenue Forecast (2017-2030)
12.5.8. Rest of MEA
12.5.8.1. Market Revenue Forecast (2017-2030)

Chapter 13. Company Profiles

13.1. GlaxoSmithKline plc
13.1.1. Company Overview, Business Information, Regional Presence
13.1.2. Product Portfolio Analysis
13.1.2.1. Product Details, Specification, Formulation
13.1.3. Revenue, Price, and Gross Margin (2015-2020)
13.1.4. Recent Developments and Strategies
13.2. Merck & Co., Inc.
13.2.1. Company Overview, Business Information, Regional Presence
13.2.2. Product Portfolio Analysis
13.2.2.1. Product Details, Specification, Formulation
13.2.3. Revenue, Price, and Gross Margin (2015-2020)
13.2.4. Recent Developments and Strategies
13.3. Eli Lilly and Company
13.3.1. Company Overview, Business Information, Regional Presence
13.3.2. Product Portfolio Analysis
13.3.2.1. Product Details, Specification, Formulation
13.3.3. Revenue, Price, and Gross Margin (2015-2020)
13.3.4. Recent Developments and Strategies
13.4. Johnson & Johnson
13.4.1. Company Overview, Business Information, Regional Presence
13.4.2. Product Portfolio Analysis
13.4.2.1. Product Details, Specification, Formulation
13.4.3. Revenue, Price, and Gross Margin (2015-2020)
13.4.4. Recent Developments and Strategies
13.5. F. Hoffmann-La Roche Ltd.
13.5.1. Company Overview, Business Information, Regional Presence
13.5.2. Product Portfolio Analysis
13.5.2.1. Product Details, Specification, Formulation
13.5.3. Revenue, Price, and Gross Margin (2015-2020)
13.5.4. Recent Developments and Strategies
13.6. Lonza
13.6.1. Company Overview, Business Information, Regional Presence
13.6.2. Product Portfolio Analysis
13.6.2.1. Product Details, Specification, Formulation
13.6.3. Revenue, Price, and Gross Margin (2015-2020)
13.6.4. Recent Developments and Strategies
13.7. Pfizer, Inc.
13.7.1. Company Overview, Business Information, Regional Presence
13.7.2. Product Portfolio Analysis
13.7.2.1. Product Details, Specification, Formulation
13.7.3. Revenue, Price, and Gross Margin (2015-2020)
13.7.4. Recent Developments and Strategies
13.8. Sanofi SA
13.8.1. Company Overview, Business Information, Regional Presence
13.8.2. Product Portfolio Analysis
13.8.2.1. Product Details, Specification, Formulation
13.8.3. Revenue, Price, and Gross Margin (2015-2020)
13.8.4. Recent Developments and Strategies
13.9. Novartis AG
13.9.1. Company Overview, Business Information, Regional Presence
13.9.2. Product Portfolio Analysis
13.9.2.1. Product Details, Specification, Formulation
13.9.3. Revenue, Price, and Gross Margin (2015-2020)
13.9.4. Recent Developments and Strategies
13.10. AstraZeneca
13.10.1. Company Overview, Business Information, Regional Presence
13.10.2. Product Portfolio Analysis
13.10.2.1. Product Details, Specification, Formulation
13.10.3. Revenue, Price, and Gross Margin (2015-2020)
13.10.4. Recent Developments and Strategies

Chapter 14. Appendix

14.1. About Us
14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.